Results 151 to 160 of about 35,844 (248)

Review of: "Long-Term Risk of Medication-Related Osteonecrosis of the Jaw (MRONJ) After Bisphosphonates and/or Denosumab in Metastatic Breast Cancer Patients" [PDF]

Nazım Can Demircan
openalex   +1 more source

Prognostic Value and Quantitative CT Analysis in RANKL Expression of Spinal GCTB in the Denosumab Era: A Machine Learning Approach [PDF]

, 2022
Qizheng Wang, Yongye Chen, Siyuan Qin, Xiaoming Liu, Ke Liu, Peijin Xin, Weili Zhao, Huishu Yuan, Ning Lang   +8 more
openalex   +1 more source

Denosumab: an investigational drug for the management of postmenopausal osteoporosis

Biologics: Targets & Therapy, 2008
E Michael LewieckiNew Mexico Clinical Research & Osteoporosis Center, Albuquerque, New Mexico, USAAbstract: Denosumab (AMG 162) is an investigational fully human monoclonal antibody with a high affinity and specificity for receptor activator of ...
E Michael Lewiecki
doaj  

Beyond bone effects: the role of denosumab in muscle Health - A systematic review. [PDF]

Aging Clin Exp Res
Ceolin C, Ziliotto C, Papa MV, Bertocco A, Sergi G, De Rui M.   +5 more
europepmc   +1 more source

Efficacy and safety of denosumab compared with conventional medications in the treatment of osteoporosis: A meta-analysis with trial sequential analysis. [PDF]

Medicine (Baltimore)
Li L, Xu J, Ji H, Xia S, Shi F.
europepmc   +1 more source

Review of: "DENOSUMAB-RELATED OSTEONECROSIS OF JAW (ONJ) VERSUS ZOLEDRONIC ACID-RELATED ONJ: DIFFERENT CHARACTERISTICS AT COMPUTED TOMOGRAPHY SCAN EVALUATION? A PROPOSAL FOR A MULTICENTRE STUDY"

, 2022
Ourania Nicolatou‐Galitis
openalex   +1 more source

Risk factors for denosumab-related osteonecrosis of the jaw: a pharmacovigilance study using the U.S. FDA adverse event reporting system database. [PDF]

Front Endocrinol (Lausanne)
Bai H, Wang J, Han X, Li H, Nie X, Wang G.   +5 more
europepmc   +1 more source

Two-year outcomes of denosumab treatment for osteoporosis comparing the effects of calcium and vitamin D supplementation. [PDF]

Sci Rep
Cho YH, Byun SE, Lee HH.
europepmc   +1 more source

The effect of denosumab treatment on muscle strength and muscle mass in patients followed up with osteoporosis

, 2023
Z. Şahiner, Mücella Güner, Serdar Ceylan, Arzu Okyar Baş, Merve Hafızoğlu, D. Karaduman, C. Atbaş, Yasemin Polat Özer, Cafer Balcı, Burcu Balam Doğu, Mustafa Cankurtaran, Meltem Halil   +11 more
openalex   +1 more source

Denosumab attenuates knee osteoarthritis progression by inhibiting synovial inflammation via the RANK/TRAF6/FSTL1 signalling. [PDF]

Nat Commun
Hu Y, Chen W, Lan S, Ming C, Xu D, Li H, Xu H, Shi D, Liu W, Dai Z, Wang J, He Z, Xu W, Shao Z, Liu Y, Tian H, Tong W.   +16 more
europepmc   +1 more source